Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience
Purpose: To evaluate the impact of dosimetric parameters on efficacy of stereotactic body radiation therapy (SBRT) in early-stage non-small cell lung cancer (ES-NSCLC), using Hypofractionated Treatment Effects in the Clinic (HyTEC) reporting standards. Methods: From April 2010 to December 2020, 497...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630823001453 |
| _version_ | 1797272444967321600 |
|---|---|
| author | François Lucia Carole Mievis Nicolas Jansen Bernard Duysinx François Cousin Thomas Louis Manon Baiwir Christelle Ernst Michel Wonner Roland Hustinx Pierre Lovinfosse Philippe Coucke |
| author_facet | François Lucia Carole Mievis Nicolas Jansen Bernard Duysinx François Cousin Thomas Louis Manon Baiwir Christelle Ernst Michel Wonner Roland Hustinx Pierre Lovinfosse Philippe Coucke |
| author_sort | François Lucia |
| collection | DOAJ |
| description | Purpose: To evaluate the impact of dosimetric parameters on efficacy of stereotactic body radiation therapy (SBRT) in early-stage non-small cell lung cancer (ES-NSCLC), using Hypofractionated Treatment Effects in the Clinic (HyTEC) reporting standards. Methods: From April 2010 to December 2020, 497 patients who received SBRT for ES-NSCLC at the University Hospital of Liège were retrospectively enrolled. A total dose of 40 to 60 Gy in 3–5 fractions (72–180 Gy biologically effective dose with an α/β ratio of 10 (BED10)) was prescribed to the 80 % isodose line of the PTV. Potential clinical and dosimetric predictors of recurrence, overall survival (OS) and disease specific survival (DSS) were evaluated using univariate and multivariate analyses. Results: After a median follow-up of 32 months (range 3–143 months), the local control and disease-free survival (DFS) rates at 3 years were 91 % (95 % CI: 90 %–93 %) and 75 % (95 % CI: 73 %–77 %), respectively. The median OS was 41.6 months and the median DSS was not reached. On multivariate analysis, a higher gross tumor volume (GTV) Dmax (BED10) (cut-off 198 Gy) and a larger percent of the GTV receiving ≥110 % of the prescribed dose were predictive of a better local control, only GTV volume was correlated with DSS and no parameter was correlated with OS and regional or distant recurrences. Conclusion: Lung SBRT for ES-NSCLC in 3 to 5 fractions resulted in high local control rates. A higher percent of GTV receiving ≥110 % of the prescribed dose and a higher GTV Dmax (BED10) seem to allow a better local control. |
| first_indexed | 2024-03-07T14:29:26Z |
| format | Article |
| id | doaj.art-c7aee60bbd164468b270ac7cfe7d4571 |
| institution | Directory Open Access Journal |
| issn | 2405-6308 |
| language | English |
| last_indexed | 2024-03-07T14:29:26Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj.art-c7aee60bbd164468b270ac7cfe7d45712024-03-06T05:27:43ZengElsevierClinical and Translational Radiation Oncology2405-63082024-03-0145100720Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experienceFrançois Lucia0Carole Mievis1Nicolas Jansen2Bernard Duysinx3François Cousin4Thomas Louis5Manon Baiwir6Christelle Ernst7Michel Wonner8Roland Hustinx9Pierre Lovinfosse10Philippe Coucke11Radiation Oncology Department, University Hospital, Brest, France; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France; Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, Belgium; Corresponding author at: Service de radiothérapie, CHRU Morvan, 2 avenue Foch, 29609 Cedex, Brest, France.Department of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumDepartment of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumDivision of Pulmonology, CHU Liège, Liège, BelgiumDivision of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, BelgiumDivision of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, BelgiumDepartment of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumDepartment of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumDepartment of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumDivision of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, BelgiumDivision of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, Liège, BelgiumDepartment of Radiotherapy Oncology, University Hospital of Liège, Liège, BelgiumPurpose: To evaluate the impact of dosimetric parameters on efficacy of stereotactic body radiation therapy (SBRT) in early-stage non-small cell lung cancer (ES-NSCLC), using Hypofractionated Treatment Effects in the Clinic (HyTEC) reporting standards. Methods: From April 2010 to December 2020, 497 patients who received SBRT for ES-NSCLC at the University Hospital of Liège were retrospectively enrolled. A total dose of 40 to 60 Gy in 3–5 fractions (72–180 Gy biologically effective dose with an α/β ratio of 10 (BED10)) was prescribed to the 80 % isodose line of the PTV. Potential clinical and dosimetric predictors of recurrence, overall survival (OS) and disease specific survival (DSS) were evaluated using univariate and multivariate analyses. Results: After a median follow-up of 32 months (range 3–143 months), the local control and disease-free survival (DFS) rates at 3 years were 91 % (95 % CI: 90 %–93 %) and 75 % (95 % CI: 73 %–77 %), respectively. The median OS was 41.6 months and the median DSS was not reached. On multivariate analysis, a higher gross tumor volume (GTV) Dmax (BED10) (cut-off 198 Gy) and a larger percent of the GTV receiving ≥110 % of the prescribed dose were predictive of a better local control, only GTV volume was correlated with DSS and no parameter was correlated with OS and regional or distant recurrences. Conclusion: Lung SBRT for ES-NSCLC in 3 to 5 fractions resulted in high local control rates. A higher percent of GTV receiving ≥110 % of the prescribed dose and a higher GTV Dmax (BED10) seem to allow a better local control.http://www.sciencedirect.com/science/article/pii/S2405630823001453Early-stage non-small cell lung cancerStereotactic body radiation therapyDosimetric analysisLocal controlRelapse |
| spellingShingle | François Lucia Carole Mievis Nicolas Jansen Bernard Duysinx François Cousin Thomas Louis Manon Baiwir Christelle Ernst Michel Wonner Roland Hustinx Pierre Lovinfosse Philippe Coucke Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience Clinical and Translational Radiation Oncology Early-stage non-small cell lung cancer Stereotactic body radiation therapy Dosimetric analysis Local control Relapse |
| title | Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience |
| title_full | Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience |
| title_fullStr | Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience |
| title_full_unstemmed | Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience |
| title_short | Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience |
| title_sort | predictive clinical and dosimetric parameters for risk of relapse in early stage non small cell lung cancer treated by sbrt a large single institution experience |
| topic | Early-stage non-small cell lung cancer Stereotactic body radiation therapy Dosimetric analysis Local control Relapse |
| url | http://www.sciencedirect.com/science/article/pii/S2405630823001453 |
| work_keys_str_mv | AT francoislucia predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT carolemievis predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT nicolasjansen predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT bernardduysinx predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT francoiscousin predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT thomaslouis predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT manonbaiwir predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT christelleernst predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT michelwonner predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT rolandhustinx predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT pierrelovinfosse predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience AT philippecoucke predictiveclinicalanddosimetricparametersforriskofrelapseinearlystagenonsmallcelllungcancertreatedbysbrtalargesingleinstitutionexperience |